Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes

NCT04770701 | Withdrawn Phase 4

• 1 other identifier: HIV / AIDS
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.

Conditions

HIV-1-infection; AIDS

Outcome Measures

Primary Outcomes (1)

• The CD4 cell count measurement

  HIV is a fatal infection, characterized by the targeting and destruction of CD4 T lymphocytes in the peripheral blood.

  - 9 months

Study Arms (1)

Ahah drug

EXPERIMENTAL

Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection. Characterized by rapid loss of resistance: AIDS * Dermatitis, mouth ulcers, skin rash, itching, weight loss * Hepatitis C virus (HCV) (+), Hepatitis B virus (HBV) (+), Tuberculosis (+) Ahah composition contains the following ingredients (concentrated extracts of plants): Eclipta prostrata, dioscorea cirrhosa, phyllanthus urinaria, adenosma glutinosum, impatiens balsamina and ascorbic acid

Drug: Ahah Drug; Device: Ahah Placebo

Interventions

Ahah Drug DRUG

\- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata, dioscorea cirrhosa, phyllanthus urinaria, adenosma glutinosum, impatiens balsamina and ascorbic acid. -Take 1tablet x 2 times / 24 hours. Maintained for 9 months.

Also known as: Ahah

Ahah drug

Ahah Placebo DEVICE

\- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata, dioscorea cirrhosa, phyllanthus urinaria, adenosma glutinosum, impatiens balsamina and ascorbic acid. -Take 1tablet x 2 times / 24 hours. Maintained for 9 months.

Also known as: Ahah

Ahah drug

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participants have a decline in CD4 + T-lymphocytes is the hallmark of HIV-1 infection.
• Characterized by rapid loss of resistance: AIDS
• Dermatitis, mouth ulcers, skin rash, itching, weight loss
• HCV (+), HBV (+), Tuberculosis (+)

You may not qualify if:

• Cancer under all form

Sponsors & Collaborators

• Trieu, Nguyen Thi, M.D.: lead

Study Sites (1)

Saigon Biopharma Company Limited

Ho Chi Minh City, 700000, Vietnam

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Interventions

A1A0 ATPase, Methanosarcina mazei

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Tran Minh Duc, Dr.

  Trieu, Nguyen Thi, M.D.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Masking Details: The group of HIV / AIDS uses drugs under study. The group of HIV / AIDS uses a placebo.
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDIV
• Responsible Party: SPONSOR

Model Details: 60 people were recruited HIV / AIDS positive between the ages of 20 and 60 and divided into 2 groups according to a random distribution.

Study Record Dates

• First Submitted: January 3, 2021
• First Posted: February 25, 2021
• Study Start: September 20, 2020
• Primary Completion: June 7, 2025
• Study Completion: June 6, 2026
• Last Updated: June 4, 2026

Record last verified: 2026-06

Locations

VN (1)